Novavax made one million doses of Nuvaxovid available for use in the United Kingdom
On Sept. 27, 2022, Novavax announced that an initial one million doses of Nuvaxovid (NVX-CoV2373) COVID-19 vaccine were…
Novavax Nuvaxovid COVID-19 vaccine received expanded EUA in Taiwan for use in adolescents aged 12 through 17
On Sept. 16, 2022, Novavax announced that the Taiwan Food and Drug Administration had granted expanded emergency use…
Novavax Nuvaxovid COVID-19 vaccine became available in Israel for individuals aged 12 and older
On Sept. 16, 2022, Novavax announced that the Israel Ministry of Health had granted an import and use…
Biotechnology | Cartoons - Original | CRISPR | Disease | Genomics | Life Science History | Therapeutics | U.S. Congress | Vaccine
U.S. Biotechnology & Biomanufacturing Initiative
On Sept. 14, 2022, The U.S. Biotech Initiative was announced detailing new investments and resources to advance the…
Novavax and Serum Institute of India announced full product registration in South Africa of Novavax COVID-19 vaccine
On Sept. 13, 2022, Novavax and Serum Institute of India Pvt. Ltd. (SII), the world’s largest vaccine manufacturer…
Malaria booster vaccine showed durable high efficacy in African children, meeting WHO-specified 75% efficacy goal
On Sept. 8, 2022, researchers from the University of Oxford and their partners reported findings from their Phase…
Swissmedic authorized Novavax Nuvaxovid COVID-19 vaccine for adolescents aged 12 through 17 and as booster in adults
On Sept. 2, 2022, Novavax announced that Swissmedic, the Swiss Agency for Therapeutic Products, had expanded its temporary…
Biotechnology | COVID-19 | Life Science News | Vaccine | WHO
World Health Organization approved SK bioscience as supplier of Novavax Nuvaxovid COVID-19 vaccine
On Sept. 2, 2022, Novavax announced that the World Health Organization had approved a variation to allow SK…
Novavax Nuvaxovidï¾™ COVID-19 vaccine recommended by CHMP for expanded conditional Marketing Authorization in EU as booster for adults
On Sept. 1, 2022, Novavax announced that Nuvaxovidï¾™ (NVX-CoV2373) COVID-19 vaccine had been recommended for expanded conditional marketing…
U.S. Department of Health and Human Services funded U.S.-based production of Smallpox and Monkeypox vaccine
On Aug. 29, 2022, the U.S. Department of Health and Human Services announced it had provided approximately $11…
Novavax Nuvaxovid COVID-19 vaccine granted expanded conditional marketing authorization in UK for use in adolescents aged 12 through 17
On Aug. 26, 2022, Novavax announced that the Medicines and Healthcare products Regulatory Agency in the United Kingdom…
Pfizer and BioNTech completed submission to EMA for Omicron BA.4/BA.5 adapted bivalent vaccine
On Aug. 26, 2022, Pfizer and BioNTech announced they had completed a submission to the European Medicines Agency…
Pfizer and BioNTech announced updated COVID-19 vaccine data supporting efficacy in children 6 months through 4 years of age
On Aug. 23, 2022, Pfizer and BioNTech announced updated efficacy results from a Phase 2/3 trial evaluating a…
Moderna announced supplying 12 million doses of Omicron-containing bivalent COVID-19 booster vaccines to Government of Canada
On Aug. 23, 2022, Moderna announced that the Government of Canada had exercised its option to purchase an…
Novavax Nuvaxovid COVID-19 vaccine granted expanded provisional approval in New Zealand for adolescents aged 12 through 17
On Aug. 18, 2022, Novavax announced that New Zealand’s Medsafe has granted expanded provisional approval for Nuvaxovid (NVX-CoV2373)…
The White House announced actions to combat Monkeypox outbreak
On Aug. 18, 2022, the White House announced that the HHS had accelerated Phase 4 of its National…
GSK awarded $170 million UNICEF contract for malaria vaccine
On Aug. 16, 2022, UNICEF announced that it had awarded a contract for the first ever supply of…
Medicines and Healthcare Products Regulatory Agency authorized Moderna’s Omicron-containing bivalent booster in the UK
On Aug. 15, 2022, Moderna announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK…
Novavax Nuvaxovid COVID-19 vaccine approved in South Korea for use in adolescents aged 12 through 17
On Aug. 12, 2022, Novavax announced that partner, SK bioscience, had received a Post Approval Change Application approval…
Moderna’s Omicron-containing bivalent booster candidate, mRNA-1273.214, demonstrated higher neutralizing antibody response
On Aug. 9, 2022, Moderna announced an amendment to its agreement with the European Commission to convert contractually…
FDA authorized Emergency Use of JYNNEOS Monkeypox vaccine
On Aug. 9, 2022, the U.S. Food and Drug Administration issued an emergency use authorization for the JYNNEOS…
Novavax announced initiation of phase 2b/3 Hummingbird global clinical trial for COVID-19 vaccine in children aged six months through 11 years
On Aug. 4, 2022, Novavax announced the initiation of its Phase 2b/3 Hummingbird global clinical trial. The trial…
U.S. Department of Health and Human Services declared Monkeypox (Mpox) a public health emergency
On Aug. 4, 2022, the U.S. Department of Health and Human Services declared the ongoing spread of monkeypox…
HHS announced 66 million doses of Moderna;s variant-specific COVID-19 vaccine booster for potential use in Fall and Winter 2022
On Jul. 29, 2022, The U.S. Department of Health and Human Services, in collaboration with the U.S. Department…
Moderna announced new supply contract with U.S. Government for 66 million doses of bivalent covid-19 booster vaccine
On Jul. 29, 2022, Moderna announced that the U.S. government has secured 66 million doses of a Moderna…
Pfizer and BioNTech announced clinical trial of next-generation vaccine candidate based on enhanced spike protein design
On Jul. 27, 2022, Pfizer and BioNTech announced that the companies had initiated a randomized, active-controlled, observer-blind, Phase…
Novavax Nuvaxovid COVID-19 vaccine granted provisional registration in Australia for use in adolescents aged 12 through 17
On Jul. 26, 2022, Novavax announced that the Australian Therapeutic Goods Agency had granted expanded approval for provisional…
Novavax announced expanded approval of Nuvaxovid COVID-19 vaccine for adolescents aged 12 through 17 in Japan
On Jul. 26, 2022, Novavax announced that Nuvaxovid (NVX-CoV2373) COVID-19 vaccine had received expanded manufacturing and marketing approval…
Biotechnology | Cartoons - Original | COVID-19 | Diagnostics | Life Science News | Medicine | NIH | Non-Profit Research | Pharmaceutical | Therapeutics | U.S. Congress | Vaccine
COVID-19 Vacations Redux
COVID-19 Vacations Redux iIlustrates once again the pits and perils vacation travelers face as they begin their Summer…
EMA Committee for Medicinal Products for Human Use recommended use of the Moderna COVID-19 booster in adolescents (12-17 years)
On Jul. 22, 2022, Moderna announced that it had received emergency use authorization from the U.S. Food and…